A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men with Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer

UVA Tracking #
HSR230043
Principal Investigator
Robert Dreicer
Contact
Contact Phone
Official Trial Title
A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men with Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer
Study Description

The University of Virginia Comprehensive Cancer Center) seeks men ages 18 and over with prostate cancer for a research study. The study will evaluate the investigational trial product called VTP-850, which is an experimental drug not yet approved by the FDA, for the treatment of prostate cancer. The main purpose of this trial is to find out how safe the trial drug VTP-850 is in people with prostate cancer who have had initial treatment but their prostate-specific antigen (PSA) levels have started to rise again.

The study involves receiving the investigational drug, as well as coming in for study visits, which include exams, laboratory tests, and procedures such as having your blood drawn, and talking to the study doctor. The trial consists of a Screening Period, a Study Treatment Period lasting 91 days with 8 on-site visits and 4 phone calls with study staff, a Short-term Follow-up Period, and a Long-term Follow-up Period. The total time of being in the trial will be up to 108 weeks.

The investigational drug, VTP-850, as well as study related doctor's visits and laboratory tests, will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05617040

uvacancertrials@hscmail.mcc.virginia.edu

Compensation

65 per study visit; up to $175 per night for a hotel